UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2010
CADENCE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-33103 | 41-2142317 | ||
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) | ||
| 12481 High Bluff Drive, Suite 200, San Diego, California (Address of Principal Executive Offices) |
92130 (Zip Code) | |||
Registrant’s telephone number, including area code: (858) 436-1400
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Increases in Salaries for Named Executive Officers. On November 17, 2010, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Cadence Pharmaceuticals, Inc. (the “Company”) set new base salaries for the Company’s named executive officers, which base salary adjustments are retroactive to March 1, 2010.
The new base salaries for the Company’s named executive officers are as follows:
| Named Executive Officer |
Title |
Base Salary | ||
| Theodore R. Schroeder |
President and Chief Executive Officer |
$489,545 | ||
| William R. LaRue |
Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary |
$320,579 | ||
| James B. Breitmeyer, M.D., Ph.D. |
Executive Vice President, Development and Chief Medical Officer |
$384,275 | ||
| Scott A. Byrd |
Senior Vice President, Chief Commercial Officer |
$332,583 | ||
| Hazel M. Aker, J.D. |
Senior Vice President, General Counsel and Secretary |
$316,985 | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CADENCE PHARMACEUTICALS, INC. | ||||||
| Date: November 22, 2010 |
By: |
/S/ WILLIAM R. LARUE | ||||
| Name: |
William R. LaRue | |||||
| Title: |
Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | |||||